In oral cancer, it was suggested that the MET activation may represent an early driver in oral premalignancy and may be target for chemoprevention of oral cancer, and the c-met was identified as a potential prognostic marker of cancer risk in patients with oral leukoplakia 12, 15-17. Here, MET is linked to lip and oral cavity carcinoma.